The Court of Appeal upheld the CMA’s excessive-pricing and dominance findings against hydrocortisone suppliers, ruling that falling prices and new entry did not end the abuse, while sending the penalties back to the CAT for a fuller review.
The Court of Appeal upheld the CMA’s excessive-pricing and dominance findings against hydrocortisone suppliers, ruling that falling prices and new entry did not end the abuse, while sending the penalties back to the CAT for a fuller review.